Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer. Dr. Fink will be responsible for all aspects of Q32 Bio's chemistry, manufacturing and control -related activities.
Other recent leadership changes in Healthcare and Therapeutics
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Q32 Bio
Location
Waltham, Massachusetts, United States
About
Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. Per the National Alopecia Areata Foundation, about 700,000 people in the United States live with alopecia areata, a disease which has a life-altering impact on patients and limited current treatment options. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Q32 Bio changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.